What is ICD-10 code C83.77?

C83.77 is the ICD-10-CM diagnosis code for Burkitt lymphoma, spleen. Burkitt lymphoma affecting the spleen, which is part of the lymphatic system. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C83.77 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C83.77 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C83.77 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C83.77 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

Which HCC does C83.77 map to under V28?

C83.77 maps to CMS-HCC V28 HCC 20 (Lung and Other Severe Cancers). The category numbers, labels, and conditions come from the CMS-HCC V28 model file for payment year 2026.

2026 ICD-10-CM C83.77: Burkitt lymphoma, spleen

C83.77 maps to CMS-HCC V28 20. A source-labeled RAF reference is available. Documentation must support MEAT. MEAT criteria · RAF Calculator · HCC Buddy coding tools

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC83.77Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)

C83.77

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Burkitt lymphoma, spleen

Burkitt lymphoma affecting the spleen, which is part of the lymphatic system.

Buddy Insight

Burkitt lymphoma of the spleen is an extremely aggressive B-cell non-Hodgkin lymphoma characterized by rapid tumor doubling time.

CMS-HCC V28

Mapped

HCC 20

Lung and Other Severe Cancers

Code-level coefficient reference

CMS-HCC V24

Historical

Not used for standard CY2026 Medicare Advantage payment. Select a historical period to review V24.

Not used for CY2026 payment

ACA/HHS

Mapped

HCC 010

HHS-HCC 010 adult, RAF varies...

Code-level coefficient reference

ESRD/PACE

Mapped

HCC 10

Lymphoma and Other Cancers

Code-level coefficient reference

RXHCC

Mapped

HCC 21

Lymphomas and Other Hematolog...

Code-level coefficient reference

Code Book Path

Official

C83Non-follicular lymphoma

C83.7Burkitt lymphoma

C83.77Burkitt lymphoma, spleen

Inclusion Terms

Official

Atypical Burkitt lymphoma
Burkitt-like lymphoma

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C83.77 in this effective period.

Related Child Codes

Official

C83.70Burkitt lymphoma, unspecified site

C83.71Burkitt lymphoma, lymph nodes of head, face, and neck

C83.72Burkitt lymphoma, intrathoracic lymph nodes

C83.73Burkitt lymphoma, intra-abdominal lymph nodes

C83.74Burkitt lymphoma, lymph nodes of axilla and upper limb

Includes

Official

ICD-10-CM does not list Includes notes for C83.77 in this effective period.

Excludes 1

Official

mature B-cell leukemia Burkitt type (C91.A-)

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C83.77 in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C83.77 in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C83.77 in this effective period.

Buddy Documentation Tip

HCC Buddy guidance

Pathology or biopsy report confirming Burkitt lymphoma histologic subtype (not just 'lymphoma' or 'non-Hodgkin lymphoma')

Imaging (CT, PET/CT, or ultrasound) confirming splenic involvement

Current disease status: active disease vs. treatment response vs. remission

Ann Arbor staging classification if documented

MEAT Support

HCC Buddy guidance

Pathology or biopsy report confirming Burkitt lymphoma histologic subtype (not just 'lymphoma' or 'non-Hodgkin lymphoma')

Imaging (CT, PET/CT, or ultrasound) confirming splenic involvement

Current disease status: active disease vs. treatment response vs. remission

Ann Arbor staging classification if documented

Audit Caution

HCC Buddy guidance

Coding Burkitt lymphoma as diffuse large B-cell lymphoma (C83.37) — these are distinct entities with different biology and treatment protocols despite both being aggressive

Using unspecified site (C83.70) when splenic involvement is clearly documented in imaging or pathology

Failing to update code to C83.7A when documentation states the patient has achieved remission

Confusing splenic marginal zone lymphoma (C83.07) with Burkitt lymphoma involving the spleen

Common Mistakes

HCC Buddy guidance

C83.87 — Other non-follicular lymphoma, spleen: Use C83.77 specifically when pathology confirms Burkitt subtype; C83.87 is for other non-follicular types like mantle cell or marginal zone

C83.77 vs. C83.7A — If Burkitt lymphoma is in remission regardless of original site, use C83.7A, not the active site-specific code

C85.17 — Unspecified B-cell lymphoma, spleen: Use only when the specific lymphoma subtype cannot be determined; Burkitt should always be coded to C83.77 when confirmed

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C83.77 an HCC code?

Yes. C83.77 (Burkitt lymphoma, spleen) maps to HCC 20, Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 1.136. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.

Coder answer: C83.77 is billable and maps to V28 HCC 20, Lung and Other Severe Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code: C83.77
Description: Burkitt lymphoma, spleen
HCC (V28): HCC 20 — Lung and Other Severe Cancers
RAF reference coefficient: 1.136
Billable: Yes
Payment year: 2026

HCC Category Mapping

V28HCC 20, Lung and Other Severe Cancers

1.136

ESRDHCC 10, Lymphoma and Other Cancers

Not separately weighted

RxHCCHCC 21, Lymphomas and Other Hematologic Cancers

Not separately weighted

These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.

Work C83.77 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →

MEAT Criteria for C83.77

For C83.77 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C83.77 during that encounter, not just copy-forwarded from a problem list.

Coder workflow notes

Get the V28 mapping + MEAT cheat sheet

One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C83.77 is the ICD-10-CM diagnosis code for burkitt lymphoma, spleen. Burkitt lymphoma affecting the spleen, which is part of the lymphatic system. C83.77 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).

Under the CMS-HCC V28 risk adjustment model, C83.77 maps to Lung and Other Severe Cancers (HCC 20) with a source-labeled community, non-dual, aged reference coefficient of 1.136. No V24 mapping is shown for C83.77; use the applicable model and payment year when reviewing the V28 mapping. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.

Confirm splenic involvement through imaging (CT, ultrasound) or pathology documentation. Because C83.77 maps to an HCC category, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) before the diagnosis is used for risk adjustment. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for C83.77 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Confirm splenic involvement through imaging (CT, ultrasound) or pathology documentation
•Use this code when the spleen is the primary or only documented site of involvement

Clinical Significance

Burkitt lymphoma of the spleen is an extremely aggressive B-cell non-Hodgkin lymphoma characterized by rapid tumor doubling time. Splenic involvement indicates advanced disease that requires urgent treatment, typically with intensive chemo-immunotherapy regimens. Accurate capture is critical for risk adjustment as this represents a high-acuity malignancy with significant resource utilization.

Documentation Requirements

✓Pathology or biopsy report confirming Burkitt lymphoma histologic subtype (not just 'lymphoma' or 'non-Hodgkin lymphoma')
✓Imaging (CT, PET/CT, or ultrasound) confirming splenic involvement
✓Current disease status: active disease vs. treatment response vs. remission
✓Ann Arbor staging classification if documented
✓Treatment plan or current treatment regimen

Commonly Confused Codes

•C83.87: Other non-follicular lymphoma, spleen: Use C83.77 specifically when pathology confirms Burkitt subtype; C83.87 is for other non-follicular types like mantle cell or marginal zone
•C83.77 vs. C83.7A: If Burkitt lymphoma is in remission regardless of original site, use C83.7A, not the active site-specific code
•C85.17: Unspecified B-cell lymphoma, spleen: Use only when the specific lymphoma subtype cannot be determined; Burkitt should always be coded to C83.77 when confirmed